Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 3;9(10):e003499. doi: 10.1136/jitc-2021-003499

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

TMB versus disease control of ACT. The resected tumor sample used for in vitro TIL expansion was examined for TMB. The TMB of 24/25 of the patients treated with ACT is shown together with the best overall response and the patients are divided according to disease control rate (PR and/or SD >4.5 months). Non-PR indicates SD or PD. ACC, adrenocorticocarcinoma; ACT, adoptive cell therapy; CC, cholangiocarcinoma; CRC, colorectal cancer; HNSCC, head-and-neck squamous cell carcinoma; MM, malignant melanoma; NCSLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; TIL, tumor-infiltrating lymphocyte; TMB, tumor mutational burden.